These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 3706170)

  • 1. Concentration-dependent pharmacologic properties of sotalol.
    Wang T; Bergstrand RH; Thompson KA; Siddoway LA; Duff HJ; Woosley RL; Roden DM
    Am J Cardiol; 1986 May; 57(13):1160-5. PubMed ID: 3706170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentration/response relations for the multiple antiarrhythmic actions of sotalol.
    Woosley RL; Barbey JT; Wang T; Funck-Brentano C
    Am J Cardiol; 1990 Jan; 65(2):22A-27A; discussion 35A-36A. PubMed ID: 2294688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans.
    Funck-Brentano C; Kibleur Y; Le Coz F; Poirier JM; Mallet A; Jaillon P
    Circulation; 1991 Feb; 83(2):536-45. PubMed ID: 1846784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sotalol: from "just another beta blocker" to "the prototype of class III antidysrhythmic compound".
    Claudel JP; Touboul P
    Pacing Clin Electrophysiol; 1995 Mar; 18(3 Pt 1):451-67. PubMed ID: 7770366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group.
    Hohnloser SH; Meinertz T; Stubbs P; Crijns HJ; Blanc JJ; Rizzon P; Cheuvart B
    Circulation; 1995 Sep; 92(6):1517-25. PubMed ID: 7664435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of sotalol for therapy of complex ventricular arrhythmias and comparisons with placebo and class I antiarrhythmic drugs.
    Anderson JL
    Am J Cardiol; 1990 Jan; 65(2):37A-42A; discussion 51A-52A. PubMed ID: 2403734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects.
    Barbey JT; Sale ME; Woosley RL; Shi J; Melikian AP; Hinderling PH
    Clin Pharmacol Ther; 1999 Jul; 66(1):91-9. PubMed ID: 10430114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sotalol: a new agent for the treatment of ventricular arrhythmias.
    Samoil D; Grubb BP; Temesy-Armos PN
    Am J Med Sci; 1994 Jan; 307(1):49-53. PubMed ID: 8291508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sotalol.
    Ruffy R
    J Cardiovasc Electrophysiol; 1993 Feb; 4(1):81-98. PubMed ID: 8287239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.
    Fitton A; Sorkin EM
    Drugs; 1993 Oct; 46(4):678-719. PubMed ID: 7506652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppressant effects of conventional beta blockers and sotalol on complex and repetitive ventricular premature complexes.
    Deedwania PC
    Am J Cardiol; 1990 Jan; 65(2):43A-50A; discussion 51A-52A. PubMed ID: 1688482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: particular reference to sotalol.
    Singh BN
    Am J Cardiol; 1990 Jan; 65(2):3A-11A; discussion 35A-36A. PubMed ID: 2403733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent supplement of estradiol and progesterone reduces the cardiac sensitivity to D,L-sotalol-induced arrhythmias in ovariectomized rabbits.
    Cheng J; Su D; Ma X; Li H
    J Cardiovasc Pharmacol Ther; 2012 Jun; 17(2):208-14. PubMed ID: 21875897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term sotalol therapy in patients with ventricular arrhythmias.
    Mary-Rabine L; Soumagne D; Stiels B
    Acta Cardiol; 1986; 41(2):89-97. PubMed ID: 2424202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
    Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
    J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
    Eckardt L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of sotalol for life-threatening ventricular arrhythmias.
    Roden DM
    Am J Cardiol; 1993 Aug; 72(4):51A-55A. PubMed ID: 8346727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerance to the repolarization effects of rac-sotalol during long-term treatment.
    Padrini R; Gusella M; Al Bunni M; Piovan D; Zordan R; Magnolfi G; Maiolino P; Ferrari M
    Br J Clin Pharmacol; 1997 Nov; 44(5):463-70. PubMed ID: 9384463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic basis of the antiarrhythmic and hemodynamic effects of sotalol.
    Antonaccio MJ; Gomoll A
    Am J Cardiol; 1993 Aug; 72(4):27A-37A. PubMed ID: 8346723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.